Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.060
-0.020 (-1.85%)
At close: May 19, 2026, 4:00 PM EDT
1.060
0.00 (0.04%)
After-hours: May 19, 2026, 5:29 PM EDT
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
12.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 21.00K | -117.00K | -84.78% |
| Dec 31, 2018 | 138.00K | 123.00K | 820.00% |
| Dec 31, 2017 | 15.00K | -4.00K | -21.05% |
| Dec 31, 2016 | 19.00K | -15.00K | -44.12% |
| Dec 31, 2015 | 34.00K | -37.00K | -52.11% |
| Dec 31, 2014 | 71.00K | -328.00K | -82.21% |
| Dec 31, 2013 | 399.00K | 302.00K | 311.34% |
| Dec 31, 2012 | 97.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cyclerion Therapeutics | 1.99M |
| BioLineRx | 1.18M |
| Jupiter Neurosciences | 40.45K |
| Kiora Pharmaceuticals | 20.00K |
| Ernexa Therapeutics | 1,000.00 |
PHIO News
- 12 days ago - Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - Newsfile Corp
- 12 days ago - Phio Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 12 days ago - Phio Pharmaceuticals Earnings release: Q1 2026 - Filings
- 4 weeks ago - Phio Pharmaceuticals Transcript: Fireside chat - Transcripts
- 5 weeks ago - Phio Pharmaceuticals Transcript: Second Annual Centri Capital Conference - Transcripts
- 5 weeks ago - Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - Newsfile Corp